Ursula A. Matulonis

Ursula A. Matulonis's AcademicInfluence.com Rankings

Ursula A. Matulonis

Medical

#2649

World Rank

#3080

Historical Rank

Oncology

#169

World Rank

#175

Historical Rank

medical Degrees

Download Badge

Medical

Ursula A. Matulonis's Degrees

Doctorate Medicine Harvard University

Why Is Ursula A. Matulonis Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ursula A. Matulonis's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial (2010) (1774)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. (2016) (1582)
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. (2012) (1323)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. (2014) (1041)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. (2007) (756)
Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. (2010) (652)
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy (2011) (521)
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. (2014) (509)
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. (2015) (480)
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer (2016) (462)
Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. (2008) (460)
OVARIAN CANCER (2016) (439)
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. (2001) (376)
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. (2016) (355)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial (2014) (326)
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer (2018) (305)
Institutional implementation of clinical tumor profiling on an unselected cancer population. (2016) (303)
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy (2012) (300)
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy (2015) (299)
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. (2012) (298)
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. (2004) (297)
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. (2019) (272)
Docetaxel administered on a weekly basis for metastatic breast cancer. (2000) (267)
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. (2019) (260)
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. (2006) (253)
A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors (2019) (242)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. (2019) (241)
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. (2018) (235)
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. (2019) (225)
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. (2009) (216)
Ovarian cancer, version 1.2016: Clinical practice guidelines in oncology (2016) (188)
A single-cell landscape of high-grade serous ovarian cancer (2020) (184)
Oncogenic mutations in cervical cancer (2013) (178)
Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. (2000) (174)
Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy (2005) (165)
Cancer- and chemotherapy-induced anemia. (2012) (164)
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer (2016) (159)
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. (2013) (158)
Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome (2012) (158)
Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. (2015) (155)
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. (2011) (148)
Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. (2016) (147)
Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. (2004) (146)
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. (2016) (145)
PARP inhibitors in ovarian cancer: current status and future promise. (2014) (141)
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. (2019) (141)
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer (2020) (139)
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. (2016) (136)
Long-term adjustment of early-stage ovarian cancer survivors (2007) (133)
Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. (2005) (133)
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. (2012) (130)
The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. (2015) (126)
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. (2007) (125)
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. (2017) (125)
Ovarian cancer, version 2.2013: Featured updates to the NCCN guidelines (2013) (122)
Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. (2005) (122)
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. (2019) (120)
Influence of patients' preferences and treatment site on cancer patients' end‐of‐life care (2010) (119)
Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations (2013) (119)
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. (2016) (119)
Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study (2013) (118)
Whole-Genome Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissue Samples (2009) (116)
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. (2019) (116)
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy (2018) (115)
Biomarkers of Response and Resistance to DNA Repair Targeted Therapies (2016) (113)
New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances (2014) (112)
The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. (2001) (111)
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. (2016) (111)
Increased HLA-DMB Expression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer (2008) (109)
TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort. (2018) (107)
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. (2010) (106)
Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. (2002) (105)
Cancer- and chemotherapy-induced anemia. (2012) (105)
Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. (2015) (103)
A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. (2015) (103)
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization (2017) (103)
Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer (2012) (102)
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. (2014) (101)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer (2017) (98)
Comparison of the quality of life of early and advanced stage ovarian cancer survivors. (2009) (94)
Ovarian cancer, version 3.2012. (2012) (92)
A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. (2002) (89)
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition (2019) (88)
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. (2020) (87)
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics (2016) (87)
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial (2019) (86)
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13 (2018) (86)
Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. (2010) (84)
Acupuncture as Palliative Therapy for Physical Symptoms and Quality of Life for Advanced Cancer Patients (2010) (83)
Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression (2017) (82)
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential (2017) (81)
Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy (2016) (80)
Epithelial ovarian cancer. (2011) (78)
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer (2019) (77)
Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. (2016) (77)
Ovarian cancer, version 2.2013. (2013) (75)
Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. (2016) (73)
Bevacizumab in patients with advanced platinum-resistant ovarian cancer. (2006) (72)
Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. (2013) (72)
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. (2010) (71)
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. (2004) (71)
Phase II trial of anastrozole in women with asymptomatic müllerian cancer. (2003) (69)
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. (2019) (69)
Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors (2017) (68)
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. (2018) (66)
Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. (2009) (65)
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. (2012) (65)
Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer (2014) (63)
Acupuncture for chemotherapy-induced leukopenia: exploratory meta-analysis of randomized controlled trials. (2007) (62)
Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer (2017) (62)
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. (2016) (61)
Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. (2018) (61)
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. (2005) (61)
Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). (2011) (58)
Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. (2012) (57)
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. (2019) (57)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study. (2018) (55)
High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary (2011) (55)
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. (2020) (54)
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. (2010) (53)
A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study) (2016) (53)
Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials (2015) (53)
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer (2020) (53)
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma (2021) (52)
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine (2017) (52)
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial (2019) (52)
The importance of chemotherapy and radiation in uterine papillary serous carcinoma. (2011) (52)
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. (2018) (51)
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. (2018) (51)
Ovarian cancer. Clinical practice guidelines in oncology. (2008) (48)
A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. (2013) (48)
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer (2015) (48)
Clinical assays for assessment of homologous recombination DNA repair deficiency. (2020) (47)
Phase I study of Doxil and vinorelbine in metastatic breast cancer. (1999) (47)
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer (2016) (47)
BRAF and AXL oncogenes drive RIPK3 expression loss in cancer (2018) (47)
Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. (2011) (46)
Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. (2005) (46)
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. (2004) (46)
Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells (2014) (46)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). (2013) (45)
Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. (2012) (45)
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model (2015) (44)
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. (2020) (43)
Long-Term Adjustment of Survivors of Ovarian Cancer Treated for Advanced-Stage Disease (2010) (43)
NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity‐modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer (2015) (43)
Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study. (2018) (42)
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. (2008) (42)
Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer (2013) (41)
Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. (2009) (41)
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response (2017) (40)
Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. (2016) (39)
Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer. (2013) (39)
PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? (2017) (38)
Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC). (2014) (38)
β-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers. (2014) (38)
Prevention of Legionella Infections in a Bone Marrow Transplant Unit: Multifaceted Approach to Decontamination of a Water System (1993) (38)
A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. (2005) (37)
The NCI-MATCH trial and precision medicine in gynecologic cancers. (2018) (37)
A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. (2020) (37)
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer (2019) (36)
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer (2016) (36)
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. (2013) (35)
Attitudes to chemotherapy in patients with ovarian cancer. (2004) (35)
Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer (2017) (34)
A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. (2011) (34)
Ovarian cancer. Clinical practice guidelines in oncology. (2006) (34)
Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy? (2019) (34)
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies (2020) (34)
New advances in ovarian cancer. (2010) (33)
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey (2018) (31)
Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. (2016) (31)
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. (2019) (30)
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC) (2019) (30)
Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer (2008) (30)
Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness (2019) (30)
CA125 immune complexes in ovarian cancer patients with low CA125 concentrations. (2010) (29)
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. (2020) (29)
Cytokines IL-1b, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFa in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel (1999) (29)
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. (2014) (29)
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference (2019) (29)
A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. (2014) (29)
A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. (2006) (28)
Management of newly diagnosed or recurrent ovarian cancer. (2018) (28)
QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens. (2018) (27)
Predicting master transcription factors from pan-cancer expression data (2019) (26)
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer (2015) (25)
Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. (2003) (25)
PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS (2010) (25)
Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer. (2018) (25)
A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. (2014) (25)
Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer (2019) (24)
Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas (2016) (24)
Topacio: Preliminary activity and safety in patients (pts) with platinum-resistant ovarian cancer (PROC) in a phase 1/2 study of niraparib in combination with pembrolizumab (2018) (24)
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine (2018) (24)
Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). (2017) (23)
Management of the toxicities of common targeted therapeutics for gynecologic cancers. (2018) (23)
Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer (2007) (23)
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial (2019) (23)
Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC). (2013) (22)
Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer (2021) (22)
Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. (2006) (22)
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer (2017) (22)
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? (2016) (22)
Abstract CT324: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort (2015) (22)
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. (2009) (22)
Hopelessness and complementary therapy use in patients with ovarian cancer. (2013) (21)
Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer. (2019) (20)
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. (2019) (20)
A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer. (2011) (20)
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer (2019) (20)
Comparison of the quality of life of early and advanced stage ovarian cancer survivors (2008) (19)
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer (2022) (19)
HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer (2008) (19)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy (2015) (19)
Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status (2005) (19)
Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer (2005) (19)
End of life issues in older patients. (2004) (19)
Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma. (2006) (18)
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. (2019) (18)
Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor. (2018) (18)
Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks (2020) (18)
Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. (2020) (18)
Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor (2017) (17)
An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers (2019) (17)
Next-Generation Sequencing: Role in Gynecologic Cancers. (2016) (17)
Anti-angiogenic Agents in Ovarian Cancer: Dawn of a New Era? (2011) (17)
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. (2019) (16)
The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled Trial. (2012) (16)
Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. (2012) (16)
A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. (2011) (16)
Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results. (2014) (16)
POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: Implications for Lynch syndrome testing (2015) (16)
Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. (2021) (16)
Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts. (2017) (15)
Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high‐dose cytosine arabinoside and melphalan (1994) (15)
Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients (2018) (15)
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial (2022) (15)
Bevacizumab and its use in epithelial ovarian cancer. (2011) (15)
Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b. (2019) (15)
Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer (2018) (14)
Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen. (2014) (14)
Prediagnosis and postdiagnosis smoking and survival following diagnosis with ovarian cancer (2020) (14)
Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis. (2016) (14)
Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. (2017) (14)
Chemotherapy hypersensitivity reactions in ovarian cancer. (2014) (14)
Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). (2017) (13)
Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours (2019) (13)
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer (2019) (13)
Abstract LB-290: Targeting MUC16 with the antibody-drug conjugate (ADC) DMUC5754A in patients with platinum-resistant ovarian cancer: A phase I study of safety and pharmacokinetics. (2013) (13)
A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca). (2018) (13)
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. (2003) (12)
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer (2021) (12)
Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and mullerian cancers (2007) (12)
1143PDDose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162) (2017) (12)
Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA trial (2017) (12)
A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC). (2019) (12)
885PDHEALTH-RELATED QUALITY OF LIFE (HRQOL) DURING OLAPARIB MAINTENANCE THERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC) AND A BRCA MUTATION (BRCAM). (2014) (12)
Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. (2004) (12)
Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy. (2017) (12)
The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC). (2017) (11)
Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study. (2022) (11)
Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). (2015) (11)
Metaplastic carcinoma of the breast with neuroglial differentiation. (2006) (10)
Phase I/II study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162). (2016) (10)
Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer (2018) (10)
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis. (10)
A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma. (2020) (10)
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. (2006) (10)
Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovaria (2017) (10)
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours (2021) (10)
Immunogenicity of clear cell ovarian cancer: Association with ARID1A loss, microsatellite instability and endometriosis. (2016) (10)
Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays (2020) (10)
gynaecological cancersA randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial) (2016) (10)
Bevacizumab in newly diagnosed ovarian cancer. (2015) (9)
Ovarian Cancer. (2018) (9)
Results of all-intraperitoneal carboplatin and paclitaxel regimen shows good tolerability and efficacy for advanced ovarian cancer (2007) (9)
COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies (2020) (9)
Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis (2021) (9)
Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1/2-mutated high grade serous ovarian cancers. (2015) (9)
A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Mullerian malignancies (2005) (9)
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors (2020) (9)
A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162). (2012) (9)
Young Women Diagnosed with Early-Stage Ovarian Cancer or Borderline Malignancy of the Ovary: A Focus on Fertility and Sexual Function (2012) (9)
A Phase I–II study of 96‐hour infusional topotecan and paclitaxel for patients with recurrent müllerian tumors (2001) (9)
Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM) (2007) (9)
Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC). (2020) (8)
Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer. (2020) (8)
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor–Positive Recurrent Endometrial Cancer (2022) (8)
Overexpression of Elafin in Ovarian Carcinoma Is Driven by Genomic Gains and Activation of the Nuclear Factor κB Pathway and Is Associated with Poor (2010) (8)
New biologic agents for the treatment of gynecologic cancers. (2012) (8)
Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer. (2021) (8)
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. (2010) (8)
Prevention of Legionella infections in a bone marrow transplant unit: multifaceted approach to decontamination of a water system. (1993) (8)
Stereologic analysis of monocytes and their subcellular organelles in patients with acute monocytic and myelomonocytic leukemia. (1990) (8)
A phase II study of ENMD-2076 in platinum-resistant ovarian cancer. (2011) (8)
Association of POLE-mutated and MSI endometrial cancers with an elevated number of tumor-infiltrating and peritumoral lymphocytes and higher expression of PD-L1. (2015) (8)
Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases (2020) (8)
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035) (2020) (8)
Abstract 2796: Development of a RAD51-based assay for determining homologous recombination proficiency and PARP inhibitor sensitivity (2017) (7)
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. (2022) (7)
Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer. (2014) (7)
Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors (2020) (7)
In vivo synergism between PARP-inhibitor olaparib and HSP90-inhibitor AT13387 in high grade serous ovarian cancer patient derived xenografts. (2016) (7)
934PDSafety and Efficacy of Niraparib in Elderly Patients (Pts) with Recurrent Ovarian Cancer (OC) (2017) (7)
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer (2022) (7)
Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC). (2019) (7)
2759 Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib (2015) (7)
Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. (2020) (7)
Rational use of cytotoxic chemotherapy for recurrent ovarian cancer. (2006) (7)
Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC) (2019) (7)
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. (2021) (7)
Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma (2018) (7)
Abstract CT232: Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors (2019) (7)
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer (2022) (6)
A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). (2014) (6)
POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure (2019) (6)
Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and POLE-mutated recurrent or persistent endometrial cancer. (2017) (6)
KRAS and EGFR mutations to distinguish adenocarcinomas and squamous cell carcinomas of the cervix. (2012) (6)
A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer (2015) (6)
Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib (2019) (6)
Characterization of ovarian cancer long-term responders on olaparib. (2014) (6)
1230PDPHASE 1B STUDY OF ORAL DUAL-PI3K/MTOR INHIBITOR GDC-0980 IN COMBINATION WITH CARBOPLATIN (CARBO)/PACLITAXEL (PAC) ± BEVACIZUMAB (BEV) AND CISPLATIN (CIS)/PEMETREXED (PEM) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS AND NSCLC. (2014) (6)
Pharmacokinetic analysis of an all intraperitoneal carboplatin and paclitaxel regimen in ovarian cancer patients demonstrates favorable systemic bioavailability of both agents. (2006) (6)
LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer (2020) (6)
PROFILE: Broadly based genomic testing for all patients at a major cancer center. (2013) (6)
QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset. (2018) (6)
Genomic testing and precision medicine--What does this mean for gynecologic oncology? (2016) (6)
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer (2010) (6)
IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts). (2016) (6)
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. (2006) (6)
933PDThe exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial (2017) (6)
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma (2022) (6)
876ORANDOMIZED PHASE 2 STUDY OF INVESTIGATIONAL, SELECTIVE AURORA A KINASE INHIBITOR ALISERTIB (MLN8237) WITH WEEKLY PACLITAXEL VS PACLITAXEL ALONE IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (OC). (2014) (5)
ENGOT-OV16/NOVA: A Maintenance sturdy with Niraparib versus placebo in patients with platinum-sensitive ovarian cancer (2016) (5)
NRG/GOG 186K: A randomized phase II study of NCI-supplied cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer—Final results (2016) (5)
Safety and efficacy of a DKK1 inhibitor (DKN-01) as monotherapy or in combination with paclitaxel in patients with Wnt activated recurrent gynecologic malignancies (2019) (5)
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer (2020) (5)
Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair–Deficient Endometrial Cancer (2020) (5)
Phase II, two-stage study of avelumab in patients with microsatellite stable (MSS), microsatellite instable (MSI) and polymerase epsilon (POLE) mutated recurrent or persistent endometrial cancer (2018) (5)
Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype (2022) (5)
Phase II clinical trial evaluating CRLX101 in recurrent ovarian, tubal, and peritoneal cancer. (2014) (5)
NOV-002 plus carboplatin in platinum-resistant ovarian cancer (2008) (5)
NCCN Guidelines Version 3.2014 Panel Members Cancer- and Chemotherapy-Induced Anemia (2014) (5)
Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4) (2022) (5)
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study. (2016) (5)
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study. (2018) (5)
A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. (2005) (5)
Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer (2019) (5)
833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer (2020) (5)
Niraparib in Recurrent Ovarian Cancer. (2017) (5)
Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) (2014) (5)
A Phase 2 Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab (Bev) Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer: One-Year Results from RTOG 0921 (2013) (5)
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer (2022) (5)
Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease course. (2019) (5)
Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort (2017) (4)
Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer. (2010) (4)
Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2-mutant metastatic breast cancer (MBC). (2019) (4)
941TiPENGOT-OV16/NOVA: A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH PARP-INHIBITOR NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER. (2014) (4)
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours (2005) (4)
A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum-resistant ovarian cancer (OC): Preliminary safety data. (2006) (4)
Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWIST analysis of the ENGOT24-OV16/NOVA trial (2019) (4)
Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer (2016) (4)
ENGOT-OV16/NOVA: Results of secondary efficacy endpoints of niraparib maintenance therapy in ovarian cancer (2017) (4)
Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648). (2014) (4)
Safety and Efficacy Results of Retreatment With a PARP Inhibitor Monotherapy in Late-Line Recurrent Ovarian Cancer: Results From a Subset of the QUADRA Trial (2020) (4)
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. (2021) (4)
Precision medicine. (2016) (4)
Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial (2018) (4)
Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): Genotype and survival. (2010) (4)
Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers (2022) (3)
Genomic characterization of long-term responders to olaparib. (2015) (3)
Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer (2008) (3)
Efficacy of Epoetin Alfa in a Retrospective Non-stratified Subgroup Analysis of a Breast Cancer Cohort Receiving Non-platinum Chemotherapy (2004) (3)
A phase II trial of voreloxin in women with platinum-resistant ovarian cancer. (2009) (3)
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer. (2020) (3)
843P Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100 (2020) (3)
Pre-diagnosis and post-diagnosis dietary patterns and survival in women with ovarian cancer (2022) (3)
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multi-study sub-analysis (2015) (3)
Somatic alterations in the PTEN-PI3K-AKT-mTOR pathway in a cohort of 379 ovarian cancer patients. (2016) (3)
A phase 1 study optimizing the dosing of olaparib tablet formulation combined with cediranib in recurrent ovarian cancer. (2015) (3)
STAC: A phase II study of carboplatin/paclitaxel/bevacizumab followed by randomization to either bevacizumab alone or erlotinib and bevacizumab in the upfront management of patients with ovarian, fallopian tube or peritoneal cancer (2011) (3)
Inability to escalate vinorelbine dose intensity using a daily × 3 schedule with and without filgrastim in patients with metastatic breast cancer (1999) (3)
Bevacizumab rechallenge after first line maintenance bevacizumab. (2012) (3)
Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer. (2000) (3)
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples in a phase I study of mirvetuximab soravtansine, a FRα-targeting antibody-drug conjugate (ADC), in relapsed epithelial ovarian cancer patients (2017) (3)
Differential blood count as triage tool in evaluation of pelvic masses (2020) (3)
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study. (2019) (3)
Use of CA-125 Tests and CT Scans for Surveillance in Ovarian Cancer (2016) (3)
Ovarian cancer clinical practice guidelines. (2004) (3)
Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101. (2021) (3)
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study (2023) (3)
EPIK-O/ENGOT-OV61: Alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). (2022) (2)
Long-term impact of chemotherapy on early stage ovarian cancer patients. (2006) (2)
Associations between age and quality of life in advanced ovarian cancer. (2010) (2)
Treatment of Advanced Epithelial Ovarian Cancer (2006) (2)
What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment? (2015) (2)
Carcinoma Erysipeloides of the Breast in a Patient With Advanced Ovarian Carcinoma (2012) (2)
MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma. (2021) (2)
Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis. (2019) (2)
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer (2020) (2)
Highlights in Ovarian Cancer From the 2017 American Society of Clinical Oncology Annual Meeting: Commentary. (2017) (2)
CA 125 Immune Complexes in Ovarian Cancer Patients with Low CA 125 Concentrations (2011) (2)
Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) models (2016) (2)
Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials. (2021) (2)
Cancer of the ovary. (2005) (2)
A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer. (2015) (2)
KEYNOTE-100: Phase 2 trial of pembrolizumab in patients with advanced recurrent ovarian cancer (2016) (2)
A phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation (2020) (2)
Downregulation of HER3: A potential surrogate for activation of HER2 through heterodimerization may predict clinical benefit in ovarian cancer from pertuzumab, a HER dimerization inhibiting antibody (2007) (2)
Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer (2019) (2)
Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer (2020) (2)
PCN7 - A TIME WITHOUT SYMPTOMS OR TOXICITY ANALYSIS OF NIRAPARIB COMPARED WITH ROUTINE SURVEILLANCE IN THE MAINTENANCE TREATMENT OF PATIENTS WITH RECURRENT OVARIAN CANCER (2018) (2)
Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. (2006) (2)
Abstract 1525: SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo (2018) (2)
Rash in a Patient With Ovarian Cancer (2012) (2)
Chemotherapy-induced Nausea and Vomiting (2009) (1)
Evaluation of serial serum IL-6 levels in women with newly diagnosed ovarian cancer on a prospective clinical trial. (2006) (1)
miRNA profiling in a case: Control study of African American women with uterine serous carcinoma (USC). (2017) (1)
Abstract 3037: Dissecting treatment resistance in patients with ovarian cancer and PDX-models using single-cell RNA-sequencing (2017) (1)
Case Report: Frontoparietal Metastasis From a Primary Fallopian Tube Carcinoma (2021) (1)
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. (2021) (1)
Abstract NT-101: QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENS (2019) (1)
O028/#376 Clinical benefit of mirvetuximab soravtansine in ovarian cancer patients with high folate receptor alpha expression: results from the soraya study (2022) (1)
A Phase 1 Study of the Anti-Erbb3 Antibody Mm-121 in Combination with Weekly Paclitaxel in Patients with Advanced Gynecological and Breast Cancers (2012) (1)
Abstract CT338: Combination of a PI3K- and a PARP-inhibitor to treat high-grade serous ovarian or triple-negative breast cancer (2014) (1)
Effects of complementary and alternative medicine use on hopelessness in ovarian cancer patients (2008) (1)
Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis (2018) (1)
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy (2018) (1)
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. (2023) (1)
Targeting VEGFRi resistance through HIF-1á suppression: Phase II clinical trial evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent platinum resistant ovarian cancer. (2015) (1)
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. (2021) (1)
The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data. (2022) (1)
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context. (2022) (1)
Targeting MYC dependency in ovarian cancer through inhibition of 1 CDK 7 and CDK 12 / 13 2 (1)
Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer (2021) (1)
Abstract 368A: Functional assessment of DNA damage repair defects and the anti-tumor immune response in high grade serous ovarian cancers using patient-derived organoids (2019) (1)
Phase II study of Cediranib (RECENTIN™, AZD2171) in recurrent epithelial ovarian cancer (2007) (1)
A first-in-human phase 1 dose escalation study of FF-10850 (liposomal topotecan) in patients with advanced solid tumors. (2022) (1)
Predictive value of circulating tumor cells for response to therapy in women with recurrent epithelial ovarian cancer. (2010) (1)
CA-125 changes can predict optimal interval cytoreduction in patients with advanced-stage epithelial ovarian cancer treated with neoadjuvant chemotherapy (2011) (1)
Abstract IA17: PARP inhibition modulates the tumor immune microenvironment in Brca1-deficient ovarian tumor (2020) (1)
Long-acting octreotide for the treatment of symptoms of bowel obstruction and intermittent obstruction in advanced ovarian cancer. (2004) (1)
Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer (2018) (1)
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects (2022) (1)
Molecular fingerprints and mechanisms of chemoresistance in ovarian cancer (2008) (1)
Chemotherapy and radiation therapy in UPSC (2007) (1)
Abstract AP19: SINGLE–CELL RNA–SEQUENCING OF PATIENT–DERIVED OVARIAN CANCER CELLS AND PATIENT–DERIVED XENOGRAFT MODELS (2017) (1)
Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer. (2018) (1)
The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers. (2011) (1)
O011/#496 Mirvetuximab soravtansine and bevacizumab in folate receptor αlpha-positive ovarian cancer: efficacy in patients with and without prior bevacizumab (2022) (1)
Tolerability and pharmacokinetics of intraperitoneal carboplatin and paclitaxel with intravenous bevacizumab. (2010) (1)
Use of neoadjuvant chemotherapy in advanced ovarian cancer. (2015) (1)
Phase II trial of GM-CSF in women with asymptomatic müllerian cancer. (2006) (1)
EPV279/#351 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline brca mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer (2021) (1)
2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine (2022) (1)
Abstract 2818: Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels (2011) (1)
Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076) (2022) (1)
Stage 1 results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas (NCT03355976). (2022) (1)
PHASE 3 TRIAL OF AVELUMAB (ANTI-PD-L1) IN COMBINATION WITH AND/OR FOLLOWING PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH UNTREATED OVARIAN CANCER (2016) (1)
Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer (2008) (1)
Abstract 156: Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and high-grade serous ovarian cancer (2021) (1)
Dkn-01 treated patients with recurrent epithelial endometrial (EEC) or ovarian (EOC) cancers which harbor Wnt activating mutations have longer progression-free survival and improved clinical benefit (2020) (1)
Photo quiz. Rash in a patient with ovarian cancer. (2012) (1)
Validation of an open-source smartphone step counting algorithm in clinical and non-clinical settings (2023) (0)
Correlation of an Aurora A single nucleotide polymorphism (SNP) with clinical responses to alisertib in patients (pts) with advanced solid tumors. (2016) (0)
Ovarian Cancer Relapse: Experimental Therapies (2013) (0)
KN100: Results from Japanese patients with advanced recurrent ovarian cancer treated with pembrolizumab monotherapy (2019) (0)
TP006/#1423 Addchemo CC trial – adjuvant treatment in plasma HPV-DNA positive patients: a biomarker for chemotherapy in locally advanced cervical cancer (2022) (0)
Abstract AP10: REAL-TIME ASSESSMENT OF HGSC DNA DAMAGE REPAIR DEFECTS AND DEFECT-INDUCED RESPONSE TO THERAPY IN OVARIAN CANCER ORGANOIDS (2019) (0)
35 Mutational analysis of epithelial ovarian cancer using OncoMap (2010) (0)
Abstract 4033: Combined MEK and BCL-2/XLinhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer (2017) (0)
Abstract 2135: Genetic relationships between ovarian and breast cancers (2010) (0)
TP030/#1426 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline BRCA mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer (2022) (0)
Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer (2020) (0)
Review: erythropoiesis-stimulating agents increase mortality in patients with cancer (2009) (0)
Local Mate Competition Experimental Evolution of Reduced Sex Ratio Adjustment Under (2011) (0)
Phase 2, two-stage study of letrozole and abemaciclib in estrogen receptor (ER) positive recurrent or persistent endometrial cancer (072) (2022) (0)
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. (2023) (0)
Abstract OT1-4-02: Phase I study of the combination of BKM120 and olaparib for the treatment of high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC) (2013) (0)
Updated 4-Year Results for NRG Oncology/RTOG 0921: A Phase 2 Study of Postoperative Intensity Modulated Radiation Therapy With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer (2016) (0)
Abstract CT142: A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer (2017) (0)
Abstract 1010: Genomic analysis of recurrent ovarian cancer in patient-derived xenografts treated with platinum and taxane chemotherapy (2017) (0)
Abstract 3459: Drug persistence pathways in ovarian cancer identified by single-cell analysis of patient samples and cell line models (2023) (0)
Long-acting octreotide for the treatment of symptoms of bowel obstruction in advanced ovarian cancer (2005) (0)
Abstract 6130: Cancer sensitivity to therapy is constrained by apoptosis regulation in cells of origin (2023) (0)
Abstract LB-255: Exome mutation burden predicts clinical outcome in ovarian cancer carrying mutated BRCA1 and BRCA2 genes. (2013) (0)
Abstract MIP-075: SOMATIC MUTATIONS AND COPY-NUMBER VARIATIONS IN OVARIAN CANCERS VIA TARGETED SEQUENCING OF EXONS OF 300 CANCER-ASSOCIATED GENES, INCLUDING MULTIPLE DNA DAMAGE REPAIR GENES (2017) (0)
Impact of Adjuvant Pelvic External Beam Radiotherapy or Vaginal Brachytherapy on Clinical Outcomes for Early-Stage Uterine Carcinosarcoma (2022) (0)
Abstract 4487: Association of the tumor-immune microenvironment with response to niraparib and pembrolizumab in relapsed, platinum-resistant ovarian cancer (2019) (0)
Abstract IA21: Combination treatments that include PI3K-inhibitors for the treatment of triple-negative breast cancer (2015) (0)
Increased HLA-DMBExpression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer (2008) (0)
Abstract 139: DNA damage and immunoprofiling with highly multiplexed tissue immunofluorescence (t-CycIF) in high-grade serous ovarian cancer (2018) (0)
Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer (2015) (0)
A phase II trial of SNS-595 in women with platinum resistant epithelial ovarian cancer (2008) (0)
Abstract 2719: Non-invasive biomarker discovery for ovarian cancer (2010) (0)
SURGICAL EVALUATION AND LONG TERM FOLLOW UP OF WOMEN WHO RECEIVED SEQUENTIAL DOUBLETS OF CHEMOTHERAPY FOR ADVANCED MULLERIAN MALIGNANCIES (2004) (0)
Abstract LB-329: MicroRNA profiling to identify novel determinants of platinum resistance in BRCA1/2-mutated high-grade serous ovarian cancer (2017) (0)
170 A6, a urokinase plasminogen activator (uPA)-derived peptide: a phase I trial in patients with advanced gynecologic cancer (2004) (0)
TP015/#1566 A phase 2, two-stage, study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer (EC) (2022) (0)
BRCA status in epithelial ovarian cancer: implications for management and future clinical trial design (2013) (0)
The Molecular Basis of Cancer (1996) (0)
Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker (2023) (0)
Prediction of Response to Therapy and Clinical Outcome through a Pilot Study of Complete Genetic Assessment of Ovarian Cancer (2015) (0)
Genomic biomarkers of recurrence in low-grade, early-stage endometrial adenocarcinoma. (2019) (0)
Review: Erythropoiesis-stimulating agents increase mortality in patients with cancer (2009) (0)
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response (2017) (0)
Industry Supported Symposium Luncheon III: PARP Inhibition in Ovarian Cancer: Integrating the Science, the Clinical Data, and the Patient Voice to Enhance Care (2017) (0)
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC). (2021) (0)
Protein expression and clinical features of ovarian cancer in the elderly (2007) (0)
Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The Cancer Genome Atlas-like Prognostic Subgroups. (2023) (0)
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors (2022) (0)
Anti-CCR4 antibody enhances anti-tumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft animal model (VAC12P.1121) (2015) (0)
Patient-reported and clinician-rated performance status and general health among women with gynecologic cancers on palliative chemotherapy. (2020) (0)
Abstract A04: Profiling DNA damage repair and immunophenotypes in BRCA1/2 mutated high-grade serous ovarian cancers (2018) (0)
Title: Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high grade serous ovarian cancer (2020) (0)
A phase II trial of modified triple doublets for the treatment of advanced Müllerian malignancies (2005) (0)
Abstract 1202: Patient derived xenograft model platform of high grade serous ovarian cancer supporting discovery of targeted therapies and biomarkers (2014) (0)
569 Whole-genome sequencing and analysis of an ovarian cancer patient (2010) (0)
Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC). (2016) (0)
Randomized trial of acupuncture versus sham control for prevention of myelosuppression in patients with gynecologic malignancies (2007) (0)
Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER (2019) (0)
Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer (2019) (0)
Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: A protocol effective in patients with gynecologic malignancies (2005) (0)
Immunotherapy for ovarian cancer. (2022) (0)
Abstract 1471: Establishment, characterization, and clinical correlation of a platform of ovarian patient-derived xenograft (PDX) models (2015) (0)
An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers (2020) (0)
Epithelial Ovarian CancerPractice Guidelines in Oncology (2011) (0)
TP031/#1443 A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell carcinoma of the ovary (2022) (0)
Activity of combination trametinib/navitoclax in patients with RAS-mutated gynecologic (GYN) cancers in a Phase 1/2 study (LBA 12) (2022) (0)
Abstract 162: Individualizing treatment using patient derived organoids, BH3 profiling and microfluidics: A proof of concept in a patient with low-grade serous ovarian carcinoma (2023) (0)
Abstract 2837: Hitting the target: Dynamic BH3 profiling, a novel functional assay to predict chemotherapy response (2014) (0)
Abstract IA23: PI3K inhibitors as a backbone for combination treatments for breast and ovarian cancer (2020) (0)
Abstract 3434: Selective glucocorticoid receptor modulation reveals a new role for CLEC10A in patients with solid tumors (2023) (0)
5002 ORAL Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer (2007) (0)
16/#430 Phase 2 results of relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer with and without prior bevacizumab (2022) (0)
Abstract IA08: PI3K- and PARP-inhibitors for the treatment of women cancers. (2016) (0)
Thyroid toxicity with the VEGF/PDGF receptor TKI AZD-2171 (RecentinTM) in a phase II study of recurrent müllerian tumors (2007) (0)
Abstract 3843: Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models (2016) (0)
Abstract AP22: DNA DAMAGE RESPONSES AND IMMUNE PROFILING THROUGH HIGHLY MULTIPLEXED TISSUE IMMUNOFLUORESCENCE (T-CYCIF) IN HIGH-GRADE SEROUS OVARIAN CANCER (2019) (0)
Abstract GS2-09: Tamoxifen instigates uterine cancer development by activating PI3K signaling and supersedes PIK3CA driver mutations (2022) (0)
Abstract 95: Somatic mutations and copy number variations in cancer-associated genes in 695 ovarian cancer patients (2016) (0)
A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC). (2021) (0)
Abstract 2615: Systematic approaches to predict oncogenic transcriptional regulatory circuitries identify important nodes in high-grade serous ovarian cancer (2019) (0)
Abstract B72: Long-term survival and outcome update on patients (pts) with recurrent ovarian cancer who received Ipilimumab post GVAX vaccine. (2016) (0)
Abstract PR01: Systems analysis of signaling pathway adaptation to design effective PI3K-based combination therapies using ovarian cancer patient-derived xenografts (2017) (0)
Molecular Basis for Targeted Therapy in Gynecologic Cancer (2014) (0)
Intraperitoneal chemotherapy improves oncologic outcome in stage IIIC epithelial ovarian cancer patients with miliary subtype (2019) (0)
Abstract 4515: The anti-CD47 antibody SRF231 increases anti-tumor activity of standard of care chemotherapy in platinum-resistant PDX models of ovarian cancer (2020) (0)
Abstract IA01: PARP inhibitors as single agents and in combinations for ovarian cancer: What lies ahead? (2018) (0)
A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors (2004) (0)
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer (2023) (0)
Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer (2017) (0)
A phase II study of fixed dose-rate gemcitabine in patients with relapsed Müllerian tumors. (2004) (0)
TP010/#242 AFT-50 EndoMAP: a phase IB/II multicohort study of targeted agents with atezolizumab (ATEZO) for patients (PTS) with recurrent or persistent endometrial cancer (EC) (2022) (0)
563 A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer (2022) (0)
Reducing infusion wait time: Redesigning medication order verification workflow at a comprehensive cancer center. (2018) (0)
A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma (2020) (0)
ErbB3 protein expression in serous ovarian carcinomas of elderly women (2007) (0)
9 – Gynecologic Tumors and Malignancies (2010) (0)
Abstract POSTER-BIOL-1331: Nucleotide excision repair mutations confer sensitivity to platinum but not PARP-inhibitors in epithelial ovarian cancer (2015) (0)
Clinical A ctivity o f T rastuzumab a nd V inorelbine i n Women W ith H ER2-Overexpress ing M etastatic B reast Cancer (2001) (0)
Successful desensitization to paclitaxel (Taxol®) in ten patients using a standardized protocol (2003) (0)
Abstract PR01: Adaptive resistance of patient-derived ovarian cancer cells to PI3K/mTOR inhibition (2015) (0)
Patients with recurrent gynecologic cancers and Wnt activating mutations demonstrated greater clinical benefit when treated with DKN-01 therapy (2021) (0)
418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ Patients with HPV16+ recurrent, or metastatic solid tumors (2020) (0)
Abstract PR06: Dissecting mechanisms of replication fork stabilization in patient-derived high-grade serous organoid cultures and their impact on therapeutic sensitivity and the immune-tumor interaction (2020) (0)
Abstract B48: Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models. (2016) (0)
A phase I/II trial of multiple dose VB-111 and weekly paclitaxel in recurrent platinum-resistant Müllerian cancer. (2015) (0)
Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. (2023) (0)
Safety and management of niraparib monotherapy in ovarian cancer clinical trials (2023) (0)
970O CARBOPLATIN PLUS PACLITAXEL VERSUS CARBOPLATIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN AS FIRST- LINE TREATMENT FOR PATIENTS WITH OVARIAN CANCER: THE MITO-2 (MULTICENTRE ITALIAN TRIALS IN OVARIAN CANCER) RANDOMIZED PHASE III TRIAL (2010) (0)
Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intravenous and intraperitoneal desensitizations in 413 cases (2008) (0)
Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions (2021) (0)
Abstract NTOC-112: GENOMIC SCARS AND CLINICAL RESPONSE TO COMBINATION THERAPY OF PARP AND ANGIOGENESIS INHIBITORS IN OVARIAN CANCER (2017) (0)
Critical Questions in Ovarian Cancer Research and Treatment: Report of an AACR Special Conference (2019) (0)
Prognostic importance of p16 status for women with vulvar squamous cell carcinoma (SCC) treated with radiotherapy. (2017) (0)
Abstract A80: TNFAIP2 is required for growth and migration of ovarian cancer cells and functions to regulate trafficking of receptor tyrosine kinases (2013) (0)
Abstract 3065: Establishment and characterization of a platform of endometrial cancer organoids (2022) (0)
Sequential angiogenic blockade for the treatment of recurrent ovarian cancer. (2010) (0)
SNS-595 demonstrates initial clinical activity in a phase 2 trial in platinum resistant epithelial ovarian cancer (2007) (0)
Safety Profile of Mirvetuximab Soravtansine, a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Patients with Recurrent Ovarian Cancer (2020) (0)
Abstract A73: BCL-XL dependency in a subset of ovarian clear-cell carcinoma cell lines (2020) (0)
Family Assessment of Quality of Care in the Last Month of Life (2017) (0)
Triona Ni Chonghaile Response to Cytotoxic Chemotherapy Pretreatment Mitochondrial Priming Correlates with Clinical (2011) (0)
Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States (353) (2022) (0)
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer (2020) (0)
Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer (2018) (0)
1 - PATIENTS (PTS) WITH RECURRENT GYNECOLOGIC CANCER WHOSE TUMORS HAVE ACTIVATING WNT PATHWAY MUTATIONS RESPOND BETTER TO DKN-01, A DICKKOPF-1 (DKK1) INHIBITOR (2019) (0)
Author response: Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13 (2018) (0)
Reducing infusion wait time: An initiative to increase early signing of medication orders by providers at a comprehensive cancer center. (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ursula A. Matulonis?

Ursula A. Matulonis is affiliated with the following schools:

MD Anderson Cancer Center
University of Oklahoma Health Sciences Center
University of California, Los Angeles
Massachusetts General Hospital
University of Pennsylvania